[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $826.57, signifying a +1.75% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=65386244e883d8fcdb4da8894a806f7e992231c25e3417aee83fc7f6e9e0489f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760564704,
      "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
      "id": 137101905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) concluded the recent trading session at $826.57, signifying a +1.75% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=65386244e883d8fcdb4da8894a806f7e992231c25e3417aee83fc7f6e9e0489f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=edacd68259ea9a9e8d146b2e23c960b64e99bfb3be35289623c22c0e2ec9d114",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760545860,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 137108274,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=edacd68259ea9a9e8d146b2e23c960b64e99bfb3be35289623c22c0e2ec9d114"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition",
    "summary": "Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY stock following the latest data.",
    "url": "https://finnhub.io/api/news?id=11a4e2da9a2a24750ae447ed7afd4c08bfb961e75ba0f601e7de1aeaee6f88e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760530976,
      "headline": "Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition",
      "id": 137094764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153026102/image_2153026102.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY stock following the latest data.",
      "url": "https://finnhub.io/api/news?id=11a4e2da9a2a24750ae447ed7afd4c08bfb961e75ba0f601e7de1aeaee6f88e3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says Diabetes Drug Orforglipron Meets Key Goals in Two Phase 3 Trials",
    "summary": "Eli Lilly (LLY) said Wednesday its experimental drug, orforglipron, met primary and all key secondar",
    "url": "https://finnhub.io/api/news?id=82e1f0b553dfcf133319ac28e7e4779bb03b81abcddd309990dd46c8118b4c81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760526940,
      "headline": "Eli Lilly Says Diabetes Drug Orforglipron Meets Key Goals in Two Phase 3 Trials",
      "id": 137093846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Wednesday its experimental drug, orforglipron, met primary and all key secondar",
      "url": "https://finnhub.io/api/news?id=82e1f0b553dfcf133319ac28e7e4779bb03b81abcddd309990dd46c8118b4c81"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data",
    "summary": "Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.",
    "url": "https://finnhub.io/api/news?id=e1492779ad9ab7ca94618ee81929ae3fd9a64c18cb23141f9549c138cf3efc54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760526180,
      "headline": "Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data",
      "id": 137093847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.",
      "url": "https://finnhub.io/api/news?id=e1492779ad9ab7ca94618ee81929ae3fd9a64c18cb23141f9549c138cf3efc54"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin. Separately, ACHIEVE-5 assessed orforglipron versus placebo in adults with type 2 diabetes and inadequate glycemic control with titrated insulin glargine, with or without metformin and/",
    "url": "https://finnhub.io/api/news?id=e2f79972a7fe5cf19eeb09ff4488725977c12c6b27ffe1bc39aacdc37395930e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760525100,
      "headline": "Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes",
      "id": 137093848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin. Separately, ACHIEVE-5 assessed orforglipron versus placebo in adults with type 2 diabetes and inadequate glycemic control with titrated insulin glargine, with or without metformin and/",
      "url": "https://finnhub.io/api/news?id=e2f79972a7fe5cf19eeb09ff4488725977c12c6b27ffe1bc39aacdc37395930e"
    }
  },
  {
    "ts": null,
    "headline": "Best 0% purchase credit cards",
    "summary": "Discover the best credit cards to save money, earn rewards and travel smarter",
    "url": "https://finnhub.io/api/news?id=f2046ad14613494c82314c24fcf18e3461b7735f445b2a2ae23cf637ebc63dc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755008232,
      "headline": "Best 0% purchase credit cards",
      "id": 136318982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Discover the best credit cards to save money, earn rewards and travel smarter",
      "url": "https://finnhub.io/api/news?id=f2046ad14613494c82314c24fcf18e3461b7735f445b2a2ae23cf637ebc63dc1"
    }
  },
  {
    "ts": null,
    "headline": "Meet the 1.4% Yield Dividend Stock That Could Soar in 2026",
    "summary": "The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.",
    "url": "https://finnhub.io/api/news?id=8f4eca43ff6db51365fc88d44946624992ca39c258f1d7865bd77c1b72dfefe3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760515200,
      "headline": "Meet the 1.4% Yield Dividend Stock That Could Soar in 2026",
      "id": 137093850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.",
      "url": "https://finnhub.io/api/news?id=8f4eca43ff6db51365fc88d44946624992ca39c258f1d7865bd77c1b72dfefe3"
    }
  },
  {
    "ts": null,
    "headline": "New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around",
    "summary": "Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio.",
    "url": "https://finnhub.io/api/news?id=14a225554c088f7e1f9a5f1342197247e2251fcab69b8fc5a0295efb22d157bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760513400,
      "headline": "New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around",
      "id": 137093851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio.",
      "url": "https://finnhub.io/api/news?id=14a225554c088f7e1f9a5f1342197247e2251fcab69b8fc5a0295efb22d157bf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials",
    "summary": "Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials",
    "url": "https://finnhub.io/api/news?id=ad97bdfbe2ec7706726ab3d8fbef155671975ab794b97b9f25ee0497b539af53",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760512800,
      "headline": "Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials",
      "id": 137108275,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials",
      "url": "https://finnhub.io/api/news?id=ad97bdfbe2ec7706726ab3d8fbef155671975ab794b97b9f25ee0497b539af53"
    }
  },
  {
    "ts": null,
    "headline": "Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace",
    "summary": "STORY: A fast-growing group of laid-off Novo Nordisk workers are referring to themselves as the 'Club 5,000'.Reflecting the number of redundancies the company is making in Denmark. Since the cuts were announced in September, hundreds of Novo staff have joined the unofficial Club 5,000 community online.The hashtag for it is used for everything from sharing job leads to organizing drinks and group walks.Novo Nordisk is battling to revive its fortunes in a fiercely-competitive obesity drug market. The cuts are in areas from manufacturing and research to IT and quality control.That's according to eight sources interviewed by Reuters and an analysis of hundreds of social media posts.The pace of the job losses underscores the pressure on new CEO Mike Doustdar in the obesity drug battle against rival Eli Lilly.The affected departments have not previously been disclosed and Reuters' report gives the most in-depth look so far inside the mass layoffs.It's a blow for thousands of local and global staff, as well as Denmark's economy.Powered by weight-loss drug Wegovy, which launched in 2021, Novo briefly became Europe's most valuable company last year.Its market capitalization exceeded Denmark's entire economic output.But competition from Eli Lilly and a growing number of copycats have slowed Wegovy's growth.Novo's share price has slumped more than 60% from its peak, prompting the ousting of its long-time CEO.Three Novo sources - two laid off, one still at the firm - said the company was aiming to complete the bulk of layoffs by this week's autumn school holiday.But some say the layoffs could also slip into November.Overall, Novo plans to shed 9,000 from its near-79,000 global workforce.",
    "url": "https://finnhub.io/api/news?id=a5dd13319de3d0745b7e2872968e418fb1fe80d5d148a375609cc49f62899f51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760509412,
      "headline": "Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace",
      "id": 137093852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: A fast-growing group of laid-off Novo Nordisk workers are referring to themselves as the 'Club 5,000'.Reflecting the number of redundancies the company is making in Denmark. Since the cuts were announced in September, hundreds of Novo staff have joined the unofficial Club 5,000 community online.The hashtag for it is used for everything from sharing job leads to organizing drinks and group walks.Novo Nordisk is battling to revive its fortunes in a fiercely-competitive obesity drug market. The cuts are in areas from manufacturing and research to IT and quality control.That's according to eight sources interviewed by Reuters and an analysis of hundreds of social media posts.The pace of the job losses underscores the pressure on new CEO Mike Doustdar in the obesity drug battle against rival Eli Lilly.The affected departments have not previously been disclosed and Reuters' report gives the most in-depth look so far inside the mass layoffs.It's a blow for thousands of local and global staff, as well as Denmark's economy.Powered by weight-loss drug Wegovy, which launched in 2021, Novo briefly became Europe's most valuable company last year.Its market capitalization exceeded Denmark's entire economic output.But competition from Eli Lilly and a growing number of copycats have slowed Wegovy's growth.Novo's share price has slumped more than 60% from its peak, prompting the ousting of its long-time CEO.Three Novo sources - two laid off, one still at the firm - said the company was aiming to complete the bulk of layoffs by this week's autumn school holiday.But some say the layoffs could also slip into November.Overall, Novo plans to shed 9,000 from its near-79,000 global workforce.",
      "url": "https://finnhub.io/api/news?id=a5dd13319de3d0745b7e2872968e418fb1fe80d5d148a375609cc49f62899f51"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today",
    "summary": "Despite the company's run in recent years, it's not too late to buy.",
    "url": "https://finnhub.io/api/news?id=b8d5664dbaa36e7deae09d575064cc9223f53d313bc21722e04bbb0c655ed8b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760486700,
      "headline": "1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today",
      "id": 137093853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite the company's run in recent years, it's not too late to buy.",
      "url": "https://finnhub.io/api/news?id=b8d5664dbaa36e7deae09d575064cc9223f53d313bc21722e04bbb0c655ed8b6"
    }
  }
]